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Objectives. This study sought to determine whether the canine
model of tachycardia-induced heart failure (HF) is an effective
model for sudden cardiac death (SCD) in HF.
Background. Such a well established HF model that also
exhibits arrhythmias and SCD, along with repolarization abnor-
malities that could trigger them, may facilitate the study of SCD
in HF, which still eludes effective treatment.
Methods. Twenty-five dogs were VVI-paced at 250 beats/min for
3 to 5 weeks. Electrocardiograms were obtained, and left ventric-
ular endocardial monophasic action potentials (MAPs) were
recorded at six sites at baseline and after HF. Weekly Holter
recordings were made with pacing suspended for 24 h.
Results. Six animals (24%) died suddenly, one with Holter-
documented polymorphic ventricular tachycardia (VT). Holter
recordings revealed an increased incidence of VT as HF pro-
gressed. Repolarization was significantly (p < 0.05) prolonged, as
indexed by a corrected QT interval (mean [6SD] 311 6 25 to
338 6 25 ms) and MAP duration measured at 90% repolarization
(MAPD90) (181 6 19 to 209 6 28 ms), and spatial MAPD90
dispersion rose by 40%. We further tested whether CsCl inhibition
of repolarizing K1 currents, which are reportedly downregulated
in HF, might preferentially prolong the MAPD90 in HF. With
1 mEq/kg body weight of CsCl, MAPD90 rose by 86 6 100 ms in
dogs with HF versus only 28 6 16 ms in control animals (p 5
0.002). Similar disparities in CsCl sensitivity were observed in
myocytes isolated from normal and failing hearts.
Conclusions. Tachycardia-induced HF exhibits malignant ar-
rhythmia and SCD, along with prolonged, heterogeneous repolar-
ization and heightened sensitivity to CsCl at chamber and cellular
levels. Thus, it appears to be a useful model for studying mecha-
nisms and therapy of SCD in HF.
(J Am Coll Cardiol 1997;30:576–84)
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Sudden cardiac death (SCD) accounts for 23% to 52% of total
mortality in patients with dilated cardiomyopathy (1–3). Al-
though ventricular arrhythmias are responsible for a majority
of these deaths, the underlying mechanisms remain poorly
understood (4,5). Repolarization abnormalities demonstrated
in isolated myocytes (6–9) and enhanced dispersion of repo-
larization may render the heart vulnerable to nonexcitable gap
reentry (10), increasing the probability of afterdepolarizations,
which can induce triggered arrhythmias (11). Reduced out-
ward K1 currents, notably transient outward current (Ito) and
inward rectifier current (IK1) (9) may contribute to action
potential prolongation.
Although human studies are valuable, failing cardiac tissue
is typically obtained only at end-stage with marked heteroge-
neity of disease duration, etiology and previous treatment.
Thus, a controlled animal model with fatal arrhythmia and
cellular repolarization abnormalities analogous to those ob-
served in human disease would be useful for exploring mech-
anisms and treatments of heart failure (HF) related sudden
death. A promising animal model is that induced by pacing
tachycardia in the dog (12–17), which displays mechanical
(12–14), biochemical (12,15,16) and molecular abnormalities
similar to HF in humans (17). We recently reported that this
model also displays markedly reduced Ito and action potential
prolongation in failing myocytes (18).
The present study tested whether tachycardia pacing–
induced HF also exhibits prolonged and spatially heteroge-
neous repolarization at the chamber level, whether it is also
associated with malignant arrhythmia and sudden death and
whether there is an increased sensitivity of repolarization to
cesium chloride (CsCl), a compound known to inhibit repolar-
izing currents. This would be important because it would
support the notion that the demonstrated cellular repolariza-
tion defects are associated with profoundly altered electro-
physiologic substrate at the chamber level.
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Methods
Study group. Twenty-five adult mongrel dogs of either
gender underwent sterile surgical instrumentation for rapid
ventricular pacing. Seventeen dogs were instrumented for
conscious hemodynamic recording (thoracotomy pacing
group), and eight dogs were instrumented solely with a trans-
venous pacemaker system and subcutaneous electrocardio-
graphic (ECG) leads (transvenous pacing group). Monophasic
action potentials (MAPs) were also measured in 10 nonpaced
control dogs before myocyte isolation for cellular electrophysi-
ologic studies. Not all tests were performed in each animal.
Animal protocols were approved by the Johns Hopkins Animal
Care and Use Committees and conformed to the “Position of
the American Heart Association on Research Animal Use,”
adopted by the Association in November 1984.
Instrumentation. Animals in the transvenous pacing group
were sedated with butorphanol tartrate (4 mg) and xylazine
(2.2 mg/kg body weight) intramuscularly, and a bipolar endo-
cardial lead (Medtronic, Inc.) was placed under fluoroscopic
guidance at the right ventricular apex through the left internal
jugular vein using local anesthesia. A programmable pace-
maker (Activitrax, Spectrax or Legend by Medtronic, Inc.),
with a magnet glued to the canister to disable the upper-rate
limit without altering ventricular sensing, was linked to the
lead and inserted into a subcutaneous pocket at the base of the
neck. Subcutaneous ECG leads were sewn in place and
exteriorized for subsequent Holter monitoring. Dogs were
provided at least 2 days for recovery before initiating pacing.
Animals in the thoracotomy pacing group underwent a left
lateral thoracotomy under barbiturate and halothane anesthe-
sia, and epicardial pacing leads were attached to the right
ventricular free wall. The modified pacemaker was placed in a
subcutaneous pocket and attached to the pacing lead. A left
ventricular tube for introducing a micromanometer was in-
serted through an apical stab and secured by purse-string
suture. Sonomicrometer crystals were placed at the mid left
ventricular level to provide anteroposterior dimension. All
wires, catheters and tubes were exteriorized at the midscapular
site. Sonomicrometer wires also served as intracardiac leads
for continuous ambulatory ECG monitoring. At least 11 days
were provided for full surgical recovery.
Experimental protocol. Baseline hemodynamic (n 5 12)
and surface ECG (n 5 16) data were collected in the conscious
state in the 17 dogs in the thoracotomy pacing group. For MAP
recordings, all animals were first sedated with butorphanol and
xylazine, and arterial access was obtained through sterile
femoral artery cutdown under local anesthesia. A steerable
catheter (EP Technologies, model 644001) was used to mea-
sure MAPs at six different sites in the left ventricular cavity:
apical, mid septal, high septal, anterior, high lateral and low
lateral walls. Signals were low pass filtered at 0.3 Hz, and high
pass filtered at 300 Hz. In addition to steady-state MAP
duration (n 5 21), the sensitivity of MAP duration measured at
90% repolarization (MAPD90) to CsCl-induced inhibition of
repolarizing K1 currents (19–21) was determined in a subset
of 11 animals. Monophasic action potentials at a single, stable
site were recorded before and after incremental doses of
intravenous CsCl (0.25 mEq/kg per dose) delivered over 15 s at
5-min intervals. Heart rate was kept constant during CsCl
infusion by pacing the left ventricle through the MAP catheter
at a rate 10% higher than the baseline heart rate. This dosing
scheme was chosen to unmask higher sensitivity of MAPD90
prolongation in dogs with HF while not provoking significant
hemodynamic alterations or torsade de pointes, as higher
doses of CsCl would (22). After data recordings were com-
plete, the femoral arteriotomy was repaired, the incision was
closed and the animal was allowed to fully recover.
Pacing was initiated at 250 beats/min in the VVI mode on
the day after baseline recording. In seven animals (six in the
thoracotomy pacing group and one in the transvenous pacing
group), pacing was suspended (VVI pacing at 30 beats/min at
the lowest possible energy output from the pulse generator) for
24 h at weekly intervals, and Holter monitor recordings were
made during this period. After at least 3 weeks of pacing
(mean 30 6 9 days), often when the animal exhibited outward
clinical signs of HF, hemodynamic and electrophysiologic data
were again obtained (HF time point). Conscious left ventric-
ular pressure–dimension data (n 5 9) and ECGs (n 5 13) were
obtained in the animals in the thoracotomy pacing group. Left
ventricular pressure measurements were also made in six of
eight animals in the transvenous pacing group at the time of
the terminal study to confirm the presence of HF. Monophasic
action potential recordings were made in a total of 11 animals
after development of HF, and CsCl infusion tests were com-
pleted in four of these dogs. To further test the relation
between ECG and hemodynamic changes induced by rapid
pacing, data were also examined after 1 week of pacing in 12
dogs in the thoracotomy pacing group.
Myocyte isolation. The harvesting of viable myocytes re-
quired rapid excision of the heart after controlled cardioplegia
and was not easily achieved in the dogs in the thoracotomy
pacing group because of scarring. Therefore, HF myocytes
were derived from the animals in the transvenous pacing
group, whereas control myocytes were obtained from dogs that
were never paced. Dogs were anesthetized with pentobarbital
Abbreviations and Acronyms
APD90 5 action potential duration at 90%
repolarization
dP/dt 5 rate of rise of left ventricular
pressure
HF 5 heart failure
IKl 5 inward rectifier current
Ito 5 transient outward current
LVEDP 5 left ventricular end-diastolic pressure
MAP (D90) 5 monophasic action potential
(duration at 90% repolarization)
NSVT 5 nonsustained ventricular tachycardia
SCD 5 sudden cardiac death
VT 5 ventricular tachycardia
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(30 mg/kg intravenously) and intubated, and the heart was
exposed by left thoracotomy. Heparin (10,000 U intravenously)
was injected, and iced lactated Ringer’s solution was placed
within the chest cavity. After ligating the aortic arch vessels,
the venae cavae and the proximal descending aorta, cold
cardioplegic solution (modified St. Thomas solution) was
retroperfused to induce cardiac arrest. The heart was rapidly
excised and immersed in cold cardioplegic solution.
Ventricular myocytes were isolated as previously described
(18,23). The left anterior descending coronary artery was
cannulated and perfused at 15 ml/min by 30 min in a nominally
Ca11-free modified Tyrode’s solution containing (in mol/liter)
138 of NaCl, 4 of KCl, 1 of MgCl2, 10 of glucose, 0.33 of
NaH2PO4 and 10 of HEPES, at pH 7.3, followed by 40 min in
the same solution with collagenase (type I, 178 U/ml, Worth-
ington Biochemical Corp.) and protease (type XIV, 0.12
mg/ml, Sigma Chemical Co.). The enzyme solution was recir-
culated. The myocardial segment was then washed for 15 min
with modified Tyrode’s solution containing 200 mmol/liter of
Ca11. All solutions were oxygenated with 100% oxygen and
warmed to 37°C. To control for the previously described
transmyocardial variability of the currents (24,25), all cells
were isolated from the central third of the myocardial wall. At
the end of perfusion, endocardial and epicardial layers were
dissected from the myocardial segment, and small chunks of
well digested midmyocardial tissue were mechanically disag-
gregated, filtered through a nylon mesh and stored at room
temperature in Tyrode’s solution containing 2.0 mmol/liter of
Ca11 until electrophysiologic study. Only Ca11-tolerant cells
with clear cross striations and without spontaneous contraction
or significant granulation (;20% to 40% of those isolated in
both control and failing hearts) were selected for experiments.
Electrophysiologic recording techniques. The whole-cell
configuration of the patch-clamp technique was employed
(26). Myocytes were transferred to the stage of an inverted
microscope and superfused at a rate of 1 to 2 ml/min with the
external solution containing (in mmol/liter) 136 of NaCl, 4 of
KCl, 2.0 of CaCl2, 1 of MgCl2, 10 of glucose, 2 of sodium
pyruvate and 10 of HEPES, at pH 7.4. Pipettes were filled with
a solution containing (in mmol/liter) 140 of KCl, 1 of MgCl2, 4
of MgATP, 10 of HEPES and 5 of NaCl, at pH 7.4. Action
potential recordings were performed at 37°C using the voltage
follower mode of an Axoclamp 2A voltage-clamp amplifier
(Axon Instruments) at a cycle length of 2,000 ms and sampled
at 1 to 2 kHz through a Digidata 1200 A/D (Axon Instruments)
interface for off-line analysis. The susceptibility of action
potential duration to the CsCl-induced inhibition of repolar-
izing K1 currents was assessed by adding 1 mmol/liter of CsCl
to the recording solution.
Data analysis. Sudden cardiac death was defined as death
occurring in dogs that did not show any outward clinical signs
of HF (lethargy, anorexia, tachypnea, ascites and edema) or
other disease processes within 24 h of their determined demise,
and in whom a gross autopsy revealed no other obvious cause
of death. Even without outward clinical signs of HF, the
animals may have had depressed systolic function and elevated
filling pressures. Holter monitor recordings were scanned
using a Del Mar analyzer (model 750), and the incidence of
nonsustained ventricular tachycardias (NSVT) was determined
each week during the evolution of HF. Ventricular tachycardia
(VT) was defined as three or more consecutive beats of
ventricular origin at a rate of 100 beats/min or higher.
Data analysis of hemodynamic and ECG signals was per-
formed using signal-averaged waveforms derived from 5 to 10
sequential steady-state cycles. The end-diastolic pressure was
at the point of rapid pressure upstroke, and the maximal rate
of rise of left ventricular pressure (dP/dtmax) was digitally
calculated from a five-point weighted slope. Monophasic ac-
tion potential recordings with stable rest voltage were selected
for analysis. The duration of MAP at 90% repolarization was
determined by an automated computer algorithm. At each
recording site, five to six consecutive beats of MAP were signal
averaged and the MAPD90 determined. Spatial dispersion of
MAPD90 was determined by the equation:
MAPD90 dispersion 5 O
i51
n uMAPDi 2 MAPD90 u
n 3 MAPD90
3 100,
where MAPDi is the MAPD90 at an individual site; MAPD90 is
the mean MAPD90 for the whole ventricle; and n is the total
number of MAP sites. This method obviated limitations of
MAPD90 dispersion calculations based on the difference be-
tween two extreme values (27,28) and is similar to the coeffi-
cient of variation method of Priori et al. (28).
Statistical analysis. Pooled data are presented as mean
value 6 SD unless specified otherwise. Heart failure data were
compared with the baseline data using the two-tailed t test for
two samples, with p , 0.05 considered significant. The effect of
incremental CsCl injection on MAPD90 at baseline and during
HF was tested by repeated measures analysis of variance with
the Fisher least significant difference test for pairwise multiple
comparisons.
Results
Hemodynamic data and sudden death. Tachycardia pacing
resulted in marked decreases in dP/dtmax (3,034 6 799 vs.
1,965 6 656 mm Hg/s, p , 0.001) and fractional shortening
(21.6 6 6.9% to 13.5 6 5.4%, p , 0.001), as well as a 138% rise
in left ventricular end-diastolic pressure (LVEDP) (from 13 to
28 mm Hg, p , 0.001). Hemodynamic evidence of HF was
similar between the 12 dogs in the thoracotomy pacing group
previously reported (17) and the six dogs in the transvenous
pacing group (LVEDP 36 6 3 mm Hg, dP/dtmax 1,187 6
239 mm Hg/s).
Of the 25 dogs that entered the pacing protocol, 10 died
before the protocol was completed. Six (24%) died suddenly,
having no outward manifestations of pump failure. The lack of
outward symptoms of HF served to differentiate these animals
from the two that died of pump failure. Two additional deaths
were related to complications of the preparation (noncardiac
death). Four of the sudden deaths occurred during active
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pacing—one occurred 10 days after pacing was suspended
after induction of HF and one occurred after 2 weeks of
pacing, during the 24 h that pacing was suspended for weekly
Holter monitoring. All but one of the sudden deaths occurred
after 2 weeks of pacing, so that cardiodepression and other
hemodynamic changes were most likely present (12,14,16,17).
The rate of sudden death in the thoracotomy pacing group
(24%) and the transvenous pacing group (25%) was similar.
Electrocardiographic monitoring. Nonsustained ventricu-
lar tachycardia was more frequently observed in dogs with HF
(Fig. 1A). The number of NSVT episodes per 24 h increased
significantly from 0.4 6 0.6 (n 5 5, range 0 to 1) to 6.7 6 10.2
(n 5 6, range 0 to 27) with HF (p 5 0.04). The mean duration
of NSVT runs at HF was 18 6 36 beats (mean rate 158 6 28
beats/min). One dog died suddenly while being monitored, and
the recording revealed the terminal event as polymorphic VT
or ventricular fibrillation (Fig. 1B). Hemodynamic evidence of
HF in the seven monitored dogs was quantitatively and statis-
tically similar to that observed in the overall group (change in
dP/dtmax 245% and change in LVEDP 154%).
Repolarization abnormalities. Table 1 provides electro-
physiologic data at baseline and after HF. The heart rate–
corrected QT interval (QTc) rose significantly by 8.7% with the
development of HF (Table 1). This change was not evident
after only 1 week of rapid pacing in 12 dogs (QTc 317.0 6
32.6 ms, p 5 0.38 vs. baseline) despite systolic impairment
(percent change in dP/dtmax 228.6 6 26.4% and percent
change in fractional shortening 221.3 6 16.9%, p , 0.001).
However, the LVEDP rise was also minimal at this earlier time
(change in LVEDP 4.1 6 8 mm Hg, p 5 NS).
Prolongation of repolarization was also demonstrated by
direct ventricular MAP recordings, which revealed lengthening
of MAPD90 by 15.5%. There was also a marked increase in the
spatial dispersion of MAPD90, from 3.8 6 3.4% at baseline to
5.3 6 3.7% during HF, an increase of 39.5% (p 5 0.01) (Fig.
2). There were no significant differences in these variables
between the subgroup that received Holter monitoring and the
animals that were not monitored (QTc 8.4% vs. 8.7%, p 5
0.58; MAPD90 16.2% vs. 15.5%, p 5 0.90; MAP dispersion
59.7% vs. 39.5%, p 5 0.58, respectively).
Response to CsCl. Prolonged repolarization could be due
to a reduction in outward rectifying K1 currents (9,18). This
mechanism would predict an enhanced sensitivity of MAPD90
to further inhibition of these currents by CsCl, a nonspecific
blocker of repolarizing K1 currents that can induce early
Figure 1. A, Example of VT re-
corded by Holter monitoring. The
dog had been paced for 20 days,
and this recording was made dur-
ing a 24-h period without pacing
to quantitate native ventricular
arrhythmias. B, The terminal
rhythm recorded from one dog
that died suddenly while being
monitored.
Table 1. Repolarization Changes With Heart Failure
Baseline HF p Value
ECG data n 5 16 n 5 13
Heart rate (beats/min) 139.7 6 23.9 140.4 6 32.3 0.947
QRS complex (ms) 64.2 6 13.2 67.9 6 20.2 0.238
QT interval (ms) 200.9 6 27.8 228.0 6 28.1 0.055
QTc interval (ms) 310.9 6 25.3 337.8 6 25.1 0.002
MAP data n 5 21 n 5 11
Heart rate (beats/min) 132.6 6 21.9 135.6 6 9.1 0.680
MAPD90 (ms) 181.1 6 19.2 209.2 6 28.1 0.002
ECG 5 electrocardiographic; MAP 5 monophasic action potential;
MAPD90 5 monophasic action potential duration at 90% repolarization: QTc 5
corrected QT interval (QT/RR).
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afterdepolarizations and, at sufficiently high doses, torsade de
pointes (19–21,29,30). Figure 3 displays the results of these
experiments, results which were consistent with this hypothesis.
Cesium chloride did not significantly alter the MAPD90 in the
control dogs at baseline, but it markedly increased MAPD90 by
43.5% in the dogs with HF (p , 0.05 by repeated measures
analysis of variance).
Cellular electrophysiology. The high incidence of sudden
death in HF and increased MAPD90 in failing hearts may have
been a reflection of an increased propensity to abnormal
repolarization of individual myocytes. There was no difference
in rest membrane potentials with HF (281.9 6 3.4 mV at
baseline vs. 284.4 6 4.4 mV during HF, p 5 0.20, n 5 9 in each
group). However, similar to findings in the intact hearts, mean
action potential duration at 90% repolarization (APD90) was
higher in the failing myocytes (468 6 140 ms vs. 411 6 75 ms
in control hearts, n 5 9 in each group), although this fell short
of statistical significance due to intercell variability. Neverthe-
less, failing myocytes did demonstrate a significantly higher
sensitivity of APD90 to CsCl (Fig. 4). The APD90 rose signifi-
cantly (p , 0.05) in both control (148.2 6 120.4 ms) and HF
(281.7 6 294.4 ms) myocytes, but this prolongation was nearly
two times greater in failing cells (p 5 0.03 by the Mann-
Whitney U test). Figure 4A displays an example of the
Figure 2. Box plots of MAPD90 dispersion at baseline and during HF.
The maximal and minimal points in each box show the 75th and 25th
percentiles, respectively, and the horizontal line within the box shows
mean MAPD90. The error bars are at the 95th and 5th percentiles.
Figure 3. A, Monophasic action potential
tracings from an animal at baseline and after
induction of HF before (solid lines) and
after (dashed lines) administration of a cu-
mulative dose of 1 mEq/kg of CsCl. Cesium
chloride had a minimal influence on MAP
duration at baseline. After development of
HF in the same animal, this CsCl dose
markedly prolonged the MAP. B, Group
data: MAPD90–CsCl dose-response curves
at baseline (open circles) and after develop-
ment of HF (solid squares). As in the
example shown in (A), there was no signifi-
cant change in MAPD90 with increasing
CsCl doses at baseline, but there was sub-
stantial prolongation at higher CsCl doses
during HF.
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response to CsCl in myocytes from a control heart and a failing
heart, and Figure 4B provides the group data for APD90.
Discussion
Prolongation of repolarization has been reported previously
in the tachycardia-induced model of HF (31–33). The present
study provides novel evidence of additional abnormalities:
enhanced spatial dispersion of repolarization, an increased
proclivity to NSVT and sudden death and enhanced sensitivity
of repolarization duration to CsCl. Although a mechanistic
link between these phenomena could not be established by the
present study, we suspect such a link is likely.
Significance of repolarization abnormalities. The cor-
rected QT interval increased by 8.3% with development of HF,
and this prolonged repolarization was also observed by length-
ening of MAPD90 in the absence of an increase in QRS
duration. These data are consistent with previous results from
the same animal model reported by Wang et al. (31), who
found an 18.7% increase in MAPD90 in isolated failing hearts,
and Li et al. (32), who reported an 18.7% increase in APD90 by
microelectrode studies on isolated papillary muscles. Consis-
tent QTc lengthening has not been reported in humans with
HF, but this may relate to higher variance due to concomitant
drug therapy and a lack of direct pre-HF and post-HF ECGs
(5). However, APD prolongation has been demonstrated in
isolated myocytes from failing human myocardium (9), similar
to what we found in the pacing canine model (18).
Prolongation of the action potential can yield a milieu
favorable to ventricular arrhythmias by increasing heterogene-
ity of repolarization, leading to nonexcitable gap reentry (10),
and by causing triggered arrhythmias through development of
afterdepolarizations (11). In the long QT syndrome, the risk of
sudden death is associated not only with lengthening of the QT
interval, but also with increased heterogeneity of repolariza-
tion measured by QT dispersion (28,34). Increased dispersion
of repolarization has been associated with electrical instability
or sudden death, or both, with type I antiarrhythmic therapy
(35), ischemic heart disease (36,37) and hypertrophic heart
disease (38,39). Barr et al. (40) recently suggested that disper-
sion of repolarization may be associated with electrical insta-
bility and sudden death in HF. The present findings are
consistent with these studies, and the magnitude of increased
MAPD90 dispersion is comparable to that reported in human
Figure 4. A, Action potential tracings from an
isolated myocyte of a normal (control) heart and a
failing heart. Data are shown both without and with
1 mmol/liter of CsCl (2Cs and 1Cs, respectively).
Cesium chloride increased the APD90 in both types
of cells, but the response was far more pronounced
in failing myocytes. B, Group data showing the
effect of CsCl on APD90 at baseline and during HF.
The error bars indicate SEM. As in the example,
APD90 prolongation by CsCl was greater in myo-
cytes isolated from failing hearts. *p , 0.05 versus
2CsCl.
581JACC Vol. 30, No. 2 PAK ET AL.
August 1997:576–84 REPOLARIZATION ABNORMALITIES IN CANINE HEART FAILURE
HF (5). Although we did not find the rest membrane potentials
in the failing myocytes to be less negative than those in the
control myocytes, Li et al. (32) reported that the failing
myocytes were more depolarized at rest. This discrepancy may
be due to our sample size and intercell variability. Less
negative rest membrane potentials in failing myocytes would
further increase the arrhythmogenic potential in the failing
heart.
Mechanism of repolarization abnormalities. Abnormali-
ties in serum electrolytes can contribute to repolarization
abnormalities and ventricular arrhythmia, and reduced levels
of K1 and Mg11 are not uncommon in HF. However, animals
were not treated with diuretic agents, and previous studies with
this model have not revealed such electrolyte changes (32). We
determined serum electrolytes in only a small subset of animals
and found no changes with HF. Further confirmation was
made in six subsequently studied dogs transvenously paced in
a fashion identical to that in the present study. Again, we found
no change in serum K1 (3.6 6 0.47 mmol/liter in control dogs
and 3.7 6 0.51 in those with HF, p 5 0.82) and Mg11 (1.35 6
0.23 mEq/liter in control dogs and 1.33 6 0.19 in those with
HF, p 5 0.84), and a very small but statistically significant
decline in ionized serum Ca11 (1.40 6 0.06 mmol/liter in
control dogs and 1.36 6 0.07 in those with HF, p 5 0.03). This,
likely, is not responsible for repolarization abnormalities,
because isolated myocyte APD90 measured at the identical
[Ca11]o also showed increased APD90 with heart failure.
Hypothyroidism can also lead to action potential prolongation,
but tachycardia-induced HF is associated with sick euthyroid
syndrome and not frank hypothyroidism (41).
Other mechanisms for action potential prolongation with
HF relate to abnormalities in specific ion channel currents.
Beuckelmann et al. (9), studying explanted human heart tissue,
reported a decrease in K1 currents, notably Ito, in end-stage
HF. We recently reported similar abnormalities in myocytes
isolated from pacing-induced HF in dogs and showed this
defect to be primarily due to a reduced number of functioning
channels (18). Although the time when Ito is active is brief and
occurs early in the action potential, decreasing Ito was capable
of significantly prolonging the APD90 (18). The present study
supports a major implication of such a current reduction that
repolarization in failing hearts and isolated “failing” myocytes
is far more sensitive to blockade of repolarizing K1 currents, as
induced by CsCl. This is important, because it indicates that
previously documented cellular defects lead to a profoundly
altered electrophysiologic substrate at the chamber level as
well.
Canine tachycardia-induced dilated cardiomyopathy model.
The canine pacing tachycardia-induced dilated cardiomyopa-
thy model of HF has proven useful in that it reproducibly
induces characteristic hemodynamic and biochemical (12–
17,42) abnormalities. Molecular analysis of myocytes is possi-
ble (16,17,43), and therapeutic interventions can be tested
(44–47). The model shares certain key similarities with human
HF—notably, neurohormonal activation (12,15), beta-
adrenergic receptor downregulation (16), decreased levels of
cyclic adenosine monophosphate (47,48) and altered force–
frequency relations (42,49). In addition, Li et al. (32) found
that, similar to human HF, there was no difference between
control dogs and dogs with HF in the inducibility of VT by
programmed electrical stimulation (32). The present study
adds to this list a relatively high incidence of sudden death and
malignant arrhythmia.
Heart failure from rapid pacing differs from human HF in
several important ways. Most notable are its reversal after
pacing termination and the fact that myocyte hypertrophy does
not occur as HF evolves (50). The canine model offers advan-
tages over small animal models for studying cardiac electro-
physiology. For example, the hearts of small animals do not
generally display sustained ventricular tachyarrhythmias suffi-
cient for SCD, whereas the canine heart is large enough to be
susceptible to death by ventricular tachyarrhythmias. Thus,
although it is not a perfect substitute for human HF, the canine
pacing model does share a remarkable number of similarities,
making it useful for evaluating mechanisms and potential
treatments to prevent SCD due to HF.
Study limitations. The measurement of MAPD90 can be
sensitive to the precise orientation of the MAP catheter and
the pressure applied to the endocardium. However, we re-
corded MAP at multiple sites in both groups and only used
tracings with a stable baseline. Furthermore, multiple beats at
each site were signal averaged to arrive at the MAPD90. This
reduced the likelihood that MAP position artifact influenced
our results. Lastly, the MAP data were also supported by direct
APD measurement in isolated myocytes.
High doses of CsCl can markedly elevate systemic pressures
by causing catecholamine release, and the resulting enhanced
afterload may, in itself, cause repolarization abnormalities
(22). Although we did not measure arterial blood pressures
during the CsCl infusion, the doses we used would likely not
have resulted in significant systemic pressure elevations.
Hanich et al. (22) reported minimal increases in blood pres-
sure after a cumulative dose of 0.825 mmol/kg of CsCl. In the
present study, we found significant increases in MAPD90 in
failing hearts at a cumulative dose of only 0.75 mmol/kg of
CsCl. If there were disparate effects on blood pressure rise in
control dogs and those with HF, the latter would likely have
had a reduced pressor response due to adrenergic receptor
downregulation. The hypothesis that CsCl itself, not its hemo-
dynamic effects, causes heightened repolarization abnormali-
ties in HF in vivo was further supported by similar responses
measured in isolated myocytes.
The scope of this study admittedly prevented us from
drawing direct conclusions about the exact cause of sudden
death. It was impossible to test a mechanistic link between the
severity of cellular electrophysiologic changes and sudden
death, because cells could only be obtained from freshly
arrested hearts. Furthermore, associating the degree of cham-
ber repolarization changes, particularly dispersion of repolar-
ization, with arrhythmogenic death would require a substan-
tially larger sample size. Therefore, although we did find that
HF induced by tachycardia pacing in these dogs was associated
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with a high incidence of sudden death, an increased incidence
of ventricular arrhythmias, prolonged and heterogeneous re-
polarization and increased sensitivity of MAPD90 to the repo-
larizing K1 current inhibitor CsCl, we cannot establish a
definitive cause and effect link between the repolarization
abnormalities and sudden death from this study.
Conclusions. Tachycardia-induced HF in dogs displays
marked repolarization abnormalities, including prolongation
of the action potential, increased spatial dispersion of
MAPD90 and enhanced sensitivity of APD90 to repolarizing
K1 current blockade by CsCl. These changes are accompanied
by high grade ventricular ectopy and sudden death in these
animals. Together, these data form an important link between
previously reported cellular repolarization defects and pro-
found electrophysiologic abnormalities at the chamber level.
As these changes bear many similarities to HF in humans,
useful mechanistic insights and meaningful tests of novel
treatment strategies for this vexing complication of cardiomy-
opathy should be feasible with this animal model.
We thank Medtronic, Inc. for graciously supplying the pulse generators and
pacing leads for this study, and Del Mar Avionics for providing the Holter
monitor recorders.
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